From antibody humanization and reformatting to afucosylated bispecific antibodies – we have developed and produced them all. Our technology and experience gives us an ability to discover antibodies against difficult multi-pass transmembrane proteins.
Icosagen provides antibody discovery and development services, using proprietary technologies.
Antibody discovery is powered by HybriFree technology
Our proprietary HybriFree technology is based on B-cell cloning, and is used for efficient discovery of monoclonal antibodies and their immediate production in mammalian cells.
HybriFree makes antibody discovery rapid and flexible, and allows cloning antibodies even from recovered patients’ PBMCs and existing hybridomas.
After immunization stage, biologically active antibodies with optimal physicochemical properties can be delivered as fast as 8 to 9 weeks.
IMMUNIZATION AGILITY
IMMUNIZATION AGILITY
Immunization of chickens with DNA, peptides, proteins or VLPs can be used to develop antibodies against hard-to-express proteins.
FLEXIBLE
FLEXIBLE
All identified sequences can be used for production of different immune molecules (bi-specifics, chimeras, antibody fragmens etc.)
COMPLEX TARGETS
WORKS WITH COMPLEX TARGETS
Integral membrane proteins as feasible targets.
HybriFree workflow
REMEMBER: ANTIGEN MATTERS! Even the smallest difference between an antigen and the natural target protein will affect the antibody specificity and biological function.
Our HybriFree technology delivers high quality antibodies suitable from IVD purposes, in pre-clinical and clinical in vitro and in vivo studies, to even for developing human biopharmaceutical drugs
Hybridoma sequencing platform — HybriRescue
We clone antibodies from hybridomas, provided by our customers, and produce them at requested scales.
In addition, we deliver the cDNA sequence encoding the antibody variable heavy (VH) and light (VL) domains.
ANTIBODY ENGINEERING
ANTIBODY ENGINEERING
Essential for monoclonal antibody engineering, humanization, function optimization or patent applications.
DELIVERS SEQUENCE
DELIVERS ANTIBODY SEQUENCE
With determined antibody sequence there is always opportunity to reproduce it, which eliminates the risk of excellent antibodies being permanently lost due to loss of cell culture.
PATENT APPLICATION
PATENT APPLICATION
Patent the sequences of your unique variable domains that provides opportunities for investing in R&D.
HybriRescue workflow
Humanization of antibodies discovered from non-humanized animals or libraries is a necessity for their use as therapeutics. The challenge is to retain the desired specificity and affinity, while engineering away their immunogenic properties.
Antibody humanization
Our humanization platform service benefits from a proprietary software developed in collaboration with the University of Tartu.
We routinely humanize variable regions and framework sequences from any species, using any reference sequence as the basis. Key residues important for the VH/VL interface and antibody structure are maintained as much as possible in the humanized variants. Humanized sequences are screened to be free of motifs that are prone to glycosylation, deamidation or other PTMS.
FLEXIBILITY
FLEXIBILITY
Antibody variable regions from the light (VL) and heavy (VH) chains can be humanized from any species.
VALIDATED SYSTEM
VALIDATED
In-house humanization and production cycle studies have provided antibodies with great titers and affinity database. We humanize all unconsolidated and non-human immunoglobulin variable region sequences.
FREE OF MOTIFS
FREE OF MOTIFS
Humanized sequences are screened to be free of motifs that can be prone to glycosylation or deamination.
KEY RESIDUES MAINTAINED
KEY RESIDUES MAINTAINED
Key residues important for the VH/VL interface and structure are maintained as much as possible in the humanized variants.
DEVELOPABILITY
DEVELOPABILITY
Humanized antibodies show ideal developability profile compared to parental antibody.
Humanization workflow
Keep only the best binders with highest production yields